A Phase 2/3 interventional study of Navlimetostat and Gemcitabine in Pancreatic Ductal Adenocarcinoma, sponsored by Bristol-Myers Squibb. Active, not recruiting at 269 sites in 36 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by Bristol-Myers Squibb · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Pancreatic Neoplasms by Bristol-Myers Squibb — 3 open to participants now, 5 under way, 1 of them phase 3. Pancreatic Neoplasms · Bristol-Myers Squibb.
Among the 27 studies in Pancreatic Neoplasms by Bristol-Myers Squibb, this one is the 4th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2025, is the only one in phase 2/3, and was the 25th registered.
3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.
Browse Pancreatic Neoplasms studies →3 of the 27 studies in Pancreatic Neoplasms by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Belgium, Canada and 10 more countries
Ages 18+
Bristol-Myers Squibb · Sites in United States, Canada, Spain
Ages 18+
Bristol-Myers Squibb · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 12 · Phase 3 3
First in 2005; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 470 is above the median of 47 across 2,932 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 105 across the 23 interventional studies, 82 across the 4 observational. Of the 22 that completed or were terminated, 10 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 27 studies in Pancreatic Neoplasms by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and efficacy of Navlimetostat (BMS-986504), a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination with nab-p/gem, in participants with untreated metastatic Pancreatic Ductal Adenocarcinoma (PDAC) with homozygous methylthioadenosine phosphorylase (MTAP) deletion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Navlimetostat · Drug: Gemcitabine · Drug: Nab-paclitaxel
Drug: Navlimetostat · Drug: Gemcitabine · Drug: Nab-paclitaxel
Drug: Gemcitabine · Drug: Nab-paclitaxel · Drug: Placebo
Drug: Gemcitabine · Drug: Nab-paclitaxel · Drug: Placebo
Drug: Navlimetostat · Drug: Gemcitabine · Drug: Nab-paclitaxel
Drug: Gemcitabine · Drug: Nab-paclitaxel · Drug: Placebo
Specified dose on specified days
Also known as: BMS-986504, MRTX1719
Specified dose on specified days
Specified dose on specified days
Also known as: Abraxane
Specified dose on specified days
Progression-Free Survival as assessed by Response Evaluation Criteria in Solid Tumors version v1.1 (RECIST v1.1)
Defined as the time between the randomization date and the date of progressive disease (PD) or death from any cause (whichever occurs first)
Time frame: Up to 3 years after last participant is randomized
Overall Survival (OS)
Defined as the time from the randomization date to the date of death from any cause
Time frame: Up to 3 years after last participant is randomized
Objective Response (OR) as assessed by RECIST v1.1
Time frame: Up to 3 years after last participant is randomized
Duration of Response (DOR) as assessed by RECIST v1.1
Defined as the time between the date of the first documentation of objective tumor response (complete response (CR) or partial response (PR)) and the date of disease progression or to death from any cause (whichever occurs first)
Time frame: Up to 3 years after last participant is randomized
Time to Objective Response (TTOR) as assessed by RECIST v1.1
Defined as the time between randomization to the date of the first documentation of objective tumor response
Time frame: Up to 3 years after last participant is randomized
Disease control as assessed by RECIST v1.1
Defined as the best overall response (BOR) of confirmed CR, PR, or stable disease (SD)
Time frame: Up to 3 years after last participant is randomized
Number of participants with treatment-related adverse events (TRAEs)
Time frame: Up to 28 days after the last drug administration
Number of participants with all-cause treatment-emergent adverse events (TEAEs)
Time frame: Up to 28 days after the last drug administration
Number of participants with treatment-emergent serious adverse events (TESAEs)
Time frame: Up to 28 days after the last drug administration
Number of participants with TEAEs leading to dose interruption, reduction, or discontinuation
Time frame: Up to 28 days after the last drug administration
Number of participants with laboratory abnormalities
Time frame: Up to 28 days after the last drug administration
PFS as assessed by RECIST v1.1
Time frame: Up to 3 years after last participant is randomized
Showing the first 100 of 269 sites across 36 countries. Choose a country and city above to see the rest.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Started Oct 2025 (actual). Primary completion is estimated for May 2029, 42 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Navlimetostat